Charles bonnet syndrome

Journal of the American Geriatrics Society

Volumn 45, Issue 7, 1997, Pages 894-

  Nevins, Michael ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; ONDANSETRON;

AGED; CASE REPORT; FEMALE; HALLUCINATION; HUMAN; NOTE; SYNDROME;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; FEMALE; HALLUCINATIONS; HUMANS; ONDANSETRON; SYNDROME;

EID: 84889234061     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1997.tb01526.x     Document Type: Letter

References (5)

1. Pfeiffer RF, Bodis-Wollner I,. Charles Bonnet syndrome (editorial). J Am Geriatr Soc 1996; 44: 1128-1129.
2. Holroyd S, Rabins PV,. A three-year follow-up study of visual hallucinations in patients with macular degeneration. J Nerv Ment Dis 1996; 184: 188-189.
3. Teunisse RJ, Cruysberg JR, Hoefnagels WH, et al., Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome. Lancet 1996; 347: 794-797.
4. Zolden J, Friedberg G, Weizman A, Melamed E,. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease. Adv Neurol 1996; 69: 541-544.
5. White A, Corn TH, Feetham C, Faulconbridge C,. Ondansetron in treatment of schizophrenia (letter). Lancet 1991; 337: 1173.